Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, Jackson DJ, Roufosse F, Börjesson Sjö L, Fan Y, Jison M, McCrae C, Necander S, Shavit A, Walton C, Merkel PA; MANDARA Study Group. Wechsler ME, et al. Among authors: jison m. N Engl J Med. 2024 Mar 7;390(10):911-921. doi: 10.1056/NEJMoa2311155. Epub 2024 Feb 23. N Engl J Med. 2024. PMID: 38393328 Clinical Trial.
Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial.
Guttman-Yassky E, Bahadori L, Brooks L, Clark KL, Grindebacke H, Ho CN, Katial R, Pham TH, Walton C, Datto CJ; HILLIER study group†. Guttman-Yassky E, et al. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):e1211-e1214. doi: 10.1111/jdv.19195. Epub 2023 Jun 12. J Eur Acad Dermatol Venereol. 2023. PMID: 37178404 Clinical Trial. No abstract available.
Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo-controlled OSTRO trial.
Emson C, Han JK, Hopkins C, Asimus S, Cann JA, Chain D, Wu Y, Reddy Y, McCrae C, Cohen D, Kreindler JL, Werkström V, Jison M, Wagenmann M, Bachert C. Emson C, et al. Among authors: jison m. Br J Clin Pharmacol. 2024 Aug;90(8):1952-1963. doi: 10.1111/bcp.16087. Epub 2024 May 7. Br J Clin Pharmacol. 2024. PMID: 38715387 Clinical Trial.
Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis.
Singh D, Criner GJ, Agustí A, Bafadhel M, Söderström J, Luporini Saraiva G, Song Y, Licaj I, Jison M, Martin UJ, Psallidas I. Singh D, et al. Among authors: jison m. Int J Chron Obstruct Pulmon Dis. 2023 Jul 27;18:1595-1599. doi: 10.2147/COPD.S418944. eCollection 2023. Int J Chron Obstruct Pulmon Dis. 2023. PMID: 37533773 Free PMC article.
Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial.
Gauvreau GM, Sehmi R, FitzGerald JM, Leigh R, Cockcroft DW, Davis BE, Mayers I, Boulet LP, Al-Sajee D, Salter BM, Cusack RP, Ho T, Whetstone CE, Alsaji N, Satia I, Killian KJ, Mitchell PD, Magee IP, Bergeron C, Bhutani M, Werkström V, Durżyński T, Shoemaker K, Katial RK, Jison M, Newbold P, McCrae C, O'Byrne PM. Gauvreau GM, et al. Among authors: jison m. Eur Respir J. 2024 Sep 12;64(3):2400512. doi: 10.1183/13993003.00512-2024. Print 2024 Sep. Eur Respir J. 2024. PMID: 39060015 Free PMC article. Clinical Trial.
Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia.
Lai K, Sun D, Dai R, Samoro R, Park HS, Åstrand A, Cohen D, Jison M, Shih VH, Werkström V, Yao Y, Zhang Y, Zheng W, Zhong N; MIRACLE Study Investigators; Principle investigators; Albert A Jr, Jianping B, Bi C, Lijun C, Mei C, Min C, Ping C, Zhimin C, Chih-Feng C, Sook CY, Xiuhua F, Xiwen G, Wei G, Wei H, Zhihai H, Wei HX, Kewu H, Mao H, Grace Dawn IM, Inbeom J, Luning J, Mingyan J, Shanping J, Meiling J, Jian K, Woo KJ, Sang-Ha K, Jiulong K, Ping-Hung K, Jie L, Manxiang L, Minjing L, Ruoran L, Wen L, Xianhua L, Yanming L, Yong LS, Chuanhe L, Chuntao L, Jing L, Xiaoxia L, Huiyu L, Zhuang L, Shengxi M, Liangping M, Hoon MK, Lin M, Choon-Sik P, Sim PH, Hye-Kyung P, Jung-Won P, Diahn-Warng P, Ronnie S, Guochao S, Debin S, Dejun S, Chun-Hua W, Guangfa W, Limin W, Xuefen W, Yan W, Liping W, Haihong W, Yi X, Zuke X, Canmao X, Jin-Fu X, Xingxiang X, Xiyuan X, Jianping Y, Hongzhong Y, Joo YH, Wencheng Y, Jin Z, Longju Z, Min Z, Wei Z, Jianping Z, Ziwen Z, Xiaoli Z, Yingqun Z; Other investigators; AstraZenenca; ClinChoice. Lai K, et al. Among authors: jison m. Respir Med. 2024 Apr 1:107611. doi: 10.1016/j.rmed.2024.107611. Online ahead of print. Respir Med. 2024. PMID: 38570145 Free article.
A Response to: Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab".
Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. Menzies-Gow A, et al. Among authors: jison m. Adv Ther. 2022 Aug;39(8):3862-3865. doi: 10.1007/s12325-022-02214-1. Epub 2022 Jun 22. Adv Ther. 2022. PMID: 35731339 Free PMC article. No abstract available.
20 results